Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03370718 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
A Phase 2 study of Stage IV Adrenal Cortex Carcinoma AJCC v8 and Unresectable Adrenal Cortex Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT03370718 is a Phase 2 study of Stage IV Adrenal Cortex Carcinoma AJCC v8 and Unresectable Adrenal Cortex Carcinoma that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03370718, a Phase 2 study of Stage IV Adrenal Cortex Carcinoma AJCC v8 and Unresectable Adrenal Cortex Carcinoma, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well cabozantinib works in treating patients with adrenal cortex cancer that has spread to nearby tissue, lymph nodes (locally advanced), or other places in the body (metastatic), and cannot be removed by surgery (unresectable). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- DRUG Cabozantinib
- OTHER Pharmacokinetic Study
- OTHER Pharmacogenomic Study
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-02-26 |
| Est. Completion | 2024-01-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03370718
The ClinicalTrials.gov registry entry for NCT03370718 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stage IV Adrenal Cortex Carcinoma AJCC v8 appearing as the primary indexed condition, and to 3 interventions - of which Cabozantinib is the first listed.
NCT03370718 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03370718 about?
NCT03370718 is a clinical study titled "Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma". This phase II trial studies how well cabozantinib works in treating patients with adrenal cortex cancer that has spread to nearby tissue, lymph nodes (locally advanced), or other places in the body (metastatic), and cannot be removed by surgery (unresectable). Cabozantinib may stop the growth of tum...
What is the current status of trial NCT03370718?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2018-02-26. Estimated completion is 2024-01-12.
What conditions does trial NCT03370718 study?
This clinical trial studies the following conditions: Stage IV Adrenal Cortex Carcinoma AJCC v8, Unresectable Adrenal Cortex Carcinoma, Metastatic Carcinoma in the Adrenal Cortex, Stage III Adrenal Cortex Carcinoma AJCC v8.
What interventions are being tested in trial NCT03370718?
The interventions under investigation include: Cabozantinib (DRUG), Pharmacokinetic Study (OTHER), Pharmacogenomic Study (OTHER).
Who is sponsoring clinical trial NCT03370718?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03370718 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Adrenal Cortex Carcinoma AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Stage IV Adrenal Cortex Carcinoma AJCC v8
All registered trials for this condition
Unresectable Adrenal Cortex Carcinoma
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.